As of September 30, 2025, cash, cash equivalents and marketable securities were $390.9 million, as compared to $345.5 million as of June 30, 2025. The company believes that its cash, cash equivalents and marketable securities, together with the $39.0 million gross proceeds from shares sold through the ATM since last quarterly filing, will be sufficient to fund its operating expenses and capital expenditure requirements into 2027, including through potential FDA approval of bezuclastinib for NonAdvSM and early commercial launch activities.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Advances FGFR2/3 Inhibitor Study in Cancer Treatment
- Cogent Biosciences’ Phase 2 Study on Bezuclastinib: A Potential Game-Changer for Advanced Systemic Mastocytosis
- JPMorgan ups Cogent Biosciences target, adds ‘Positive Catalyst Watch’
- Promising Outlook for Cogent Biosciences: Buy Rating Backed by FDA Breakthrough Designation and Strong Phase 3 Trial Prospects
- Cogent Biosciences announces FDA BTD for bezuclastinib